The company’s chief executive Adar Poonawalla said that supplies of Covishield in India have crossed 1.25 billion doses.
Biotechnology company Serum Institute of India has applied to the Drugs Controller General of India and the Union health ministry for full market authorisation of its Covid-19 vaccine Covishield, the company’s chief executive officer Adar Poonawalla said on Friday. Poonawalla said that the Union government now has enough data for full market authorisation. He added that supplies of Covishield in India have crossed 1.25 billion doses. Authorities in India grant emergency use approval during public health emergencies when they find that the known and potential benefits of a medical product outweigh its known and potential risks.
